Pyridostigmine treatment trial in neurogenic orthostatic hypotension

Wolfgang Singer, Paola Sandroni, Tonette L. Opfer-Gehrking, Guillermo A. Suarez, Caroline M. Klein, Stacy Hines, Peter C. O'Brien, Jeffrey Slezak, Phillip Anson Low

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Background: Midodrine hydrochloride is the only drug demonstrated in a placebo-controlled treatment trial to improve orthostatic hypotension (OH) but it significantly worsens supine hypertension. By enhancing ganglionic transmission, pyridostigmine bromide can potentially ameliorate OH without worsening supine hypertension. Objective: To evaluate the efficacy of a single 60-mg dose of pyridostigmine bromide, alone or in combination with a subthreshold (2.5 mg) or suprathreshold (5 mg) dose of midodrine hydrochloride, compared with placebo. Design: We report a double-blind, randomized, 4-way cross-over study of pyridostigmine in the treatment of neurogenic OH. A total of 58 patients with neurogenic OH were enrolled. After 1 day of baseline measurements, patients were given 4 treatments (3 active treatments [60 mg of pyridostigmine bromide; 60 mg of pyridostigmine bromide and 2.5 mg of midodrine hydrochloride; 60 mg of pyridostigmine bromide and 5 mg of midodrine hydrochloride] and a placebo) in random order on successive days. Blood pressure (BP) and heart rate were measured, both supine and standing, immediately before treatment and hourly for 6 hours after the treatment was given. Results: Nosignificant differences were seen in the supine BP, either systolic (P=.36) or diastolic (P=.85). In contrast, the primary end point of the fall in standing diastolic BP was significantly reduced (P=.02) with treatment. Pairwise comparison showed significant reduction by pyridostigmine alone (BP fall of 27.6 mm Hg vs 34.0 mm Hg with placebo; P=.04) and pyridostigmine and 5 mg of midodrine hydrochloride (BP fall of 27.2 mm Hg vs 34.0 mm Hg with placebo; P=.002). Standing BP improvement significantly regressed with improvement in OH symptoms. Conclusions: Pyridostigmine significantly improves standing BP in patients with OH without worsening supine hypertension. The greatest effect is on diastolic BP, suggesting that the improvement is due to increased total peripheral resistance.

Original languageEnglish (US)
Pages (from-to)513-518
Number of pages6
JournalArchives of Neurology
Volume63
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Pyridostigmine Bromide
Orthostatic Hypotension
Midodrine
Blood Pressure
Placebos
Therapeutics
Hypertension
Vascular Resistance
Cross-Over Studies
Placebo
Heart Rate

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Pyridostigmine treatment trial in neurogenic orthostatic hypotension. / Singer, Wolfgang; Sandroni, Paola; Opfer-Gehrking, Tonette L.; Suarez, Guillermo A.; Klein, Caroline M.; Hines, Stacy; O'Brien, Peter C.; Slezak, Jeffrey; Low, Phillip Anson.

In: Archives of Neurology, Vol. 63, No. 4, 04.2006, p. 513-518.

Research output: Contribution to journalArticle

Singer, W, Sandroni, P, Opfer-Gehrking, TL, Suarez, GA, Klein, CM, Hines, S, O'Brien, PC, Slezak, J & Low, PA 2006, 'Pyridostigmine treatment trial in neurogenic orthostatic hypotension', Archives of Neurology, vol. 63, no. 4, pp. 513-518. https://doi.org/10.1001/archneur.63.4.noc50340
Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Archives of Neurology. 2006 Apr;63(4):513-518. https://doi.org/10.1001/archneur.63.4.noc50340
Singer, Wolfgang ; Sandroni, Paola ; Opfer-Gehrking, Tonette L. ; Suarez, Guillermo A. ; Klein, Caroline M. ; Hines, Stacy ; O'Brien, Peter C. ; Slezak, Jeffrey ; Low, Phillip Anson. / Pyridostigmine treatment trial in neurogenic orthostatic hypotension. In: Archives of Neurology. 2006 ; Vol. 63, No. 4. pp. 513-518.
@article{b287a4a1acb34b93bc32b8259bd887df,
title = "Pyridostigmine treatment trial in neurogenic orthostatic hypotension",
abstract = "Background: Midodrine hydrochloride is the only drug demonstrated in a placebo-controlled treatment trial to improve orthostatic hypotension (OH) but it significantly worsens supine hypertension. By enhancing ganglionic transmission, pyridostigmine bromide can potentially ameliorate OH without worsening supine hypertension. Objective: To evaluate the efficacy of a single 60-mg dose of pyridostigmine bromide, alone or in combination with a subthreshold (2.5 mg) or suprathreshold (5 mg) dose of midodrine hydrochloride, compared with placebo. Design: We report a double-blind, randomized, 4-way cross-over study of pyridostigmine in the treatment of neurogenic OH. A total of 58 patients with neurogenic OH were enrolled. After 1 day of baseline measurements, patients were given 4 treatments (3 active treatments [60 mg of pyridostigmine bromide; 60 mg of pyridostigmine bromide and 2.5 mg of midodrine hydrochloride; 60 mg of pyridostigmine bromide and 5 mg of midodrine hydrochloride] and a placebo) in random order on successive days. Blood pressure (BP) and heart rate were measured, both supine and standing, immediately before treatment and hourly for 6 hours after the treatment was given. Results: Nosignificant differences were seen in the supine BP, either systolic (P=.36) or diastolic (P=.85). In contrast, the primary end point of the fall in standing diastolic BP was significantly reduced (P=.02) with treatment. Pairwise comparison showed significant reduction by pyridostigmine alone (BP fall of 27.6 mm Hg vs 34.0 mm Hg with placebo; P=.04) and pyridostigmine and 5 mg of midodrine hydrochloride (BP fall of 27.2 mm Hg vs 34.0 mm Hg with placebo; P=.002). Standing BP improvement significantly regressed with improvement in OH symptoms. Conclusions: Pyridostigmine significantly improves standing BP in patients with OH without worsening supine hypertension. The greatest effect is on diastolic BP, suggesting that the improvement is due to increased total peripheral resistance.",
author = "Wolfgang Singer and Paola Sandroni and Opfer-Gehrking, {Tonette L.} and Suarez, {Guillermo A.} and Klein, {Caroline M.} and Stacy Hines and O'Brien, {Peter C.} and Jeffrey Slezak and Low, {Phillip Anson}",
year = "2006",
month = "4",
doi = "10.1001/archneur.63.4.noc50340",
language = "English (US)",
volume = "63",
pages = "513--518",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Pyridostigmine treatment trial in neurogenic orthostatic hypotension

AU - Singer, Wolfgang

AU - Sandroni, Paola

AU - Opfer-Gehrking, Tonette L.

AU - Suarez, Guillermo A.

AU - Klein, Caroline M.

AU - Hines, Stacy

AU - O'Brien, Peter C.

AU - Slezak, Jeffrey

AU - Low, Phillip Anson

PY - 2006/4

Y1 - 2006/4

N2 - Background: Midodrine hydrochloride is the only drug demonstrated in a placebo-controlled treatment trial to improve orthostatic hypotension (OH) but it significantly worsens supine hypertension. By enhancing ganglionic transmission, pyridostigmine bromide can potentially ameliorate OH without worsening supine hypertension. Objective: To evaluate the efficacy of a single 60-mg dose of pyridostigmine bromide, alone or in combination with a subthreshold (2.5 mg) or suprathreshold (5 mg) dose of midodrine hydrochloride, compared with placebo. Design: We report a double-blind, randomized, 4-way cross-over study of pyridostigmine in the treatment of neurogenic OH. A total of 58 patients with neurogenic OH were enrolled. After 1 day of baseline measurements, patients were given 4 treatments (3 active treatments [60 mg of pyridostigmine bromide; 60 mg of pyridostigmine bromide and 2.5 mg of midodrine hydrochloride; 60 mg of pyridostigmine bromide and 5 mg of midodrine hydrochloride] and a placebo) in random order on successive days. Blood pressure (BP) and heart rate were measured, both supine and standing, immediately before treatment and hourly for 6 hours after the treatment was given. Results: Nosignificant differences were seen in the supine BP, either systolic (P=.36) or diastolic (P=.85). In contrast, the primary end point of the fall in standing diastolic BP was significantly reduced (P=.02) with treatment. Pairwise comparison showed significant reduction by pyridostigmine alone (BP fall of 27.6 mm Hg vs 34.0 mm Hg with placebo; P=.04) and pyridostigmine and 5 mg of midodrine hydrochloride (BP fall of 27.2 mm Hg vs 34.0 mm Hg with placebo; P=.002). Standing BP improvement significantly regressed with improvement in OH symptoms. Conclusions: Pyridostigmine significantly improves standing BP in patients with OH without worsening supine hypertension. The greatest effect is on diastolic BP, suggesting that the improvement is due to increased total peripheral resistance.

AB - Background: Midodrine hydrochloride is the only drug demonstrated in a placebo-controlled treatment trial to improve orthostatic hypotension (OH) but it significantly worsens supine hypertension. By enhancing ganglionic transmission, pyridostigmine bromide can potentially ameliorate OH without worsening supine hypertension. Objective: To evaluate the efficacy of a single 60-mg dose of pyridostigmine bromide, alone or in combination with a subthreshold (2.5 mg) or suprathreshold (5 mg) dose of midodrine hydrochloride, compared with placebo. Design: We report a double-blind, randomized, 4-way cross-over study of pyridostigmine in the treatment of neurogenic OH. A total of 58 patients with neurogenic OH were enrolled. After 1 day of baseline measurements, patients were given 4 treatments (3 active treatments [60 mg of pyridostigmine bromide; 60 mg of pyridostigmine bromide and 2.5 mg of midodrine hydrochloride; 60 mg of pyridostigmine bromide and 5 mg of midodrine hydrochloride] and a placebo) in random order on successive days. Blood pressure (BP) and heart rate were measured, both supine and standing, immediately before treatment and hourly for 6 hours after the treatment was given. Results: Nosignificant differences were seen in the supine BP, either systolic (P=.36) or diastolic (P=.85). In contrast, the primary end point of the fall in standing diastolic BP was significantly reduced (P=.02) with treatment. Pairwise comparison showed significant reduction by pyridostigmine alone (BP fall of 27.6 mm Hg vs 34.0 mm Hg with placebo; P=.04) and pyridostigmine and 5 mg of midodrine hydrochloride (BP fall of 27.2 mm Hg vs 34.0 mm Hg with placebo; P=.002). Standing BP improvement significantly regressed with improvement in OH symptoms. Conclusions: Pyridostigmine significantly improves standing BP in patients with OH without worsening supine hypertension. The greatest effect is on diastolic BP, suggesting that the improvement is due to increased total peripheral resistance.

UR - http://www.scopus.com/inward/record.url?scp=33645739276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645739276&partnerID=8YFLogxK

U2 - 10.1001/archneur.63.4.noc50340

DO - 10.1001/archneur.63.4.noc50340

M3 - Article

VL - 63

SP - 513

EP - 518

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 4

ER -